1. Gohdse H. (1989) Drugs and Addictive Behaviour: A Guide to Treatment. Chap.2. Blackwell Scientific Publications, Oxford.
  2. Spear B. (1969) The growth of heroin addiction in the United Kingdom. British Journal of Addiction, 64: 245.
  3. Eichler O and Farah A. (1957) Handbuch Der Experimentellen Pharmakologie. Springer-Verlag, Berlin.
  4. Bäumler E (1968) A Century of Chemistry. Econ Verlag, Dusseldorf.
  5. Erhahart G and Ruschig H. (1972) Arzneimittel Entwicklung Wirkung Darstellung, Band 1, Therapeutica mit Wirkung auf das Zentral Nervensystem. Verlag Chemie, Weinheim.
  6. Payte J T. (1991) A brief history of methadone in the treatment of opioid dependence: A personal perspective. Journal of Psychoactive Drugs, 23: 103–7.
  7. Bäumler E. (1992) Die Grossen Medikamente. Gustav Lübbe Verlag, Bergisch Gladbach.
  8. Chen K K. (1948) Pharmacology of methadone and related compounds. Annals: New York Academy of Sciences.
  9. May E L and Jacobson A E. (1989) The Committee on Problems of Drug Dependence: A legacy of the National Academy of Sciences. A historical account. Drug and Alcohol Dependence, 23: 183–218.
  10. Isbell H, Wikler A and Eddy N. (1947) Tolerance and addiction liability of 6-dimethylamino-4-4-diphenyl-heptanon-3 (methadon). Journal of the American Medical Association, 135: 888–94.
  11. Bockmόhl M and Ehrhart G. (1949) Uber eine neue Klasse von spasmolytisch und analgetissch wirkenden Verindungen. Justus Liebigs Ann. Chem. 561: 52.
  12. Prescott F and Ransome S G. (1947) Amidone (miadone) as an obstetric analgesic, Lancet 2: 501.
  13. Duncan Mitchell, Personal correspondence with the authors. 31/1/95.
  14. Edwards G and Busch C. (eds). (1981) Drug problems in Britain: A review of 10 years. Academic Press.
  15. Stimson G V and Oppenheimer E. (1982) Heroin addiction: Treatment and control in Britain. Tavistock, London.
  16. Hartnoll R L, Mitcheson M, Battersby A, et al. (1980) Evaluation of heroin maintenance in controlled trial. Archives of General Psychiatry, 37:877–84.
  17. Paxton R, Mullin P, and Beattie J. (1978) The effects of methadone maintenance with opioid takers: A review and findings from one British city. British Journal of Psychiatry, 132: 473–81.
  18. Home Office (1986) Statistics of drug addicts notified to the Home Office, United Kingdom, 1985. Home Office Statistical Bulletin, 40/86. London, HMSO. Home Office (1994) Statistics of drug addicts notified to the Home Office, United Kingdom, 1993. Home Office Statistical Bulletin, 10/94 London, HMSO.
  19. Advisory Council on the Misuse of Drugs. (1982) Treatment and Rehabilitation Report. HMSO, London.
  20. Advisory Council on the Misuse of Drugs. (1988) AIDS and Drug Misuse. Part 1. HMSO, London.
  21. Robertson J R, Bucknell A B V, Welsby P D, et al. (1986) Epidemic of AIDS-related virus (HTLV-III/LAV) infection among intravenous drug abusers. British Medical Journal, 292: 527–30.
  22. Hart G J, Sonnex C, Petherick A, et al. (1989) Risk behaviour for HIV infection amongst injecting drug users attending a drug dependency clinic. British Medical Journal, 298: 1081–3.
  23. Liappas J A, Jenner F A, and Vincente B. (1988) Literature on methadone maintenance clinics. International Journal of Addiction, 23: 927–40.
  24. Greenwood J. (1990) Creating a new drug service in Edinburgh. British Medical Journal, 300: 587–9.
  25. Dally A. (1987) Stabilise, not criminalise. Druglink, Sep/Oct: 14.
  26. Dally A. (1990) A doctor’s story. MacMillan. London.
  27. Anon (1994) Conversation with Vincent Dole. Addiction, 89: 23–9
  28. Cooper J R. (1992) Ineffective use of psychoactive drugs: Methadone treatment is no exception. Journal of the American Medical Association, 267: 281–2.
  29. Ball J A and Ross A. (1991) The effectiveness of methadone maintenance treatment. Springer-Verlag, New York.
  30. Strain E C, Stitzer M L, Liebson I A and Bigelow G E. (1993) Methadone dose and treatment outcome. Drug and Alcohol Dependence, 33: 105–17.
  31. Strain E C, Stitzer M L, Liebson I A and Bigelow G E. (1993) Dose-response effects of methadone in the treatment of opioid dependence. Annals of Internal Medicine, 119: 23–7.
  32. Hubbard R L, Marsden M E, Rachal J V, et al. (1989) Drug Abuse Treatment: A National Study of Effectiveness. University of North Carolina Press, Chapel Hill, NC.
  33. Vogel V H, Isbell H and Chapman K W. Present status of narcotic addiction. Journal of the American Medical Association, 138: 1019–26.
  34. Kolb L and Himmelsbach C K. (1938) Clinical studies of drug addiction III. A critical review of the withdrawal treatments with method of evaluating abstinence syndromes. Public Health Reports, 128: 1.
  35. Gossop M. (1990) The development of a short opiate withdrawal scale (SOWS). Addictive Behaviors, 15: 487–90.
  36. Gossop M, Bradley M and Phillips G. (1987) An investigation of withdrawal symptoms shown by opiate addicts during and subsequent to a 21-day in-patient methadone detoxification procedure. Addictive Behaviors 12: 1–6.
  37. Phillips G, Gossop M and Bradley M. (1986) The influence of psychological factors on the opiate withdrawal syndrome. British Journal of Psychiatry, 149: 235–8.
  38. Green L and Gossop M. (1988) Effects of information on the opiate withdrawal syndrome. British Journal of Addiction, 83: 305–9.
  39. Gossop M, Griffiths P, Bradley M and Strang J. (1989) Opiate withdrawal symptoms in response to 10-day and 21-day methadone withdrawal programmes. British Journal of Psychiatry, 154: 360–3.
  40. Gossop M and Strang J. (1991) A comparison of the withdrawal responses of heroin and methadone addicts during detoxification. British Journal of Psychiatry, 158: 697–9.
  41. Gossop M, Johns A and Green L. (1986) Opiate withdrawal: In-patient versus out-patient programmes and preferred versus random assignment to treatment. British Medical Journal, 293: 103–4.
  42. Dawe S, Griffiths P, Gossop M and Strang J. (1991) Should opiate addicts be involved in controlling their own detoxification? A comparison of fixed vs. negotiable schedules. British Journal of Addiction, 86: 977–82.
  43. Yancovitz S R, Des Jarlais D C, Peyser N P, et al. (1991) A randomised trial of an interim methadone clinic. American Journal of Public Health, 81: 1185–91.
  44. Dole V P, Robinson J W, Orraca J, et al (1975) New England Journal of Medicine, 280: 1372–5.
  45. Newman R G, and Whitehill W B. (1979) Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet, September 8: 485–8.
  46. Gunne L M and Gronbladh L (1981) The Swedish methadone maintenance program: A controlled study. Drug and Alcohol Dependence, 24: 249–256.
  47. Stitzer M L, Iguchi, M Y and Felch L J. (1992) Contingent take-home incentive: Effects on drug use of methadone maintenance patients. Journal of Consulting and Clinical Psychology, 60: 927–34.
  48. Ball J A and Ross A. (1991) The effectiveness of methadone maintenance treatment. Springer-Verlag, New York.
  49. McLellan T A, Arndt I, Metzger D, et al. (1993) The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association, 269: 1953–9.
  50. Department of Health, Scottish Office Home & Health Dept, Welsh Office. (1991) Drug Misuse and Dependence: Guidelines on clinical management. HMSO, London.
  51. Balzaar J. (1986) Formulation for extemporaneously prepared sugar free methadone mixture. Pharm J, 237: 678.
  52. Goodman O S. (ed). (1985) The pharmacological basis of therapeutics., McMillan, New York, Chap. 22 by Jaffe J H and Martin W R.
  53. Bozarth and Wize. (1984) quoted p499 in ref 72.
  54. British National Formulary. (September 1989) 18: 188.
  55. Dollerey C Sir. (1991) Therapeutic Drugs. Churchill Livingstone, Edinburgh.
  56. Cicero et al. (1975) Function of the male sex organs in heroin and methadone users. New England Journal of Medicine. 292: 882–7
  57. McCaul M E, Bigelow G, Stitzer M, et al. (1982) Short-term effects of oral methadone in methadone maintenence subjects. Clin Journal Pharmacol. Theraputics. 31(2): 753–61.
  58. Dale A and Jones S S. (1992) The Methadone Experience: the consumer view. The Centre for Research, London.
  59. Briggs G G, Freeman R K and Yaffe S J. (eds). Drugs in pregnancy and lactation: a reference guide to foetal and neonatal risk. 3rd Edition.
  60. Johnstone F D, (1990) Contemp. Rev. Obstet. Gynaecol. 2: May.
  61. Newman R G, Bashkow S and Calko D. (1975) Results of 313 consecutive live births delivered to patients in the New York City methadone maintenence programme. American Journal of Obstetrics and Gynaecology, 121: 233–7.
  62. Naeye K L, Blanc W and Khatamee M A. Fetal complications of maternal heroin addiction; abnormal growth, infections, and episodes of stress. Journal of Pediatrics, 83: 1055–61.
  63. Alroomi L G, Davidson J,Evans T J, et al (1988) Maternal narcotic abuse and the newborn. Archives of Disease in Childhood, 63.
  64. O’Brien C P and Jaffe J H. (eds). (1990) Addictive States. Association for research in nervous and mental disease 70, Raven Press, New York.
  65. Kreek M J. (1983) Health Consequences associated with the use of methadone. In: Cooper J R, et al (eds). Research on the treatment of narcotic addiction: State of the art. NIDA treatment research monograph series. DHHS publication number (ADM) 83–1281: 456–82. Rockville National Institute on Drug Abuse.
  66. Bigwood C S and Coehelho A J. (1990) Methadone and caries. British Dental Journal, 231.
  67. Lewis D. (1990) Methadone and caries. British Dental Journal, 231.
  68. Dollery C Sir. (1991) Therapeutic drugs. Methadone Hydrochloride, M92. Churchill Livingstone, Edinburgh.
  69. Reynolds J. Ed. Martindale (1993) The Extra Pharmacopoeia. Pharmaceutical Press, 1082.
  70. Clarice ECG (ed). Isolation and identification of drugs in pharmaceuticals, body fluids and post mortem material. Part 2 page 408.Pharmaceutical Press, London.
  71. Dollery C Sir. (1991) Therapeutic drugs. Diamorphine Hydrochloride, D74. Churchill Livingstone, Edinburgh.
  72. Personal Communication. The National Poisons Unit, New Cross Hospital, London, 1994.
  73. Aronow R, Brenner S L and Woolley P V. (1973) An apparent epidemic: Methadone poisioning in children. Clinical Toxicology, 6(2): 175.
  74. Laurence D R and Bennett P N. (1991) Poisoning, Drug Overdose, Antidotes. Clinical Pharmacology, 9: 138.
  75. Stockley IH (1994) Drug interactions: a source book of adverse interactions, their mechanisms, clinical importance and management 3rd ed, Blackwell Scientific Publications, Oxford
  76. British Medical Association and the Royal Pharmaceutical Society (1995) Appendix 1: Interactions. British National Formulary, 29 March.
  77. Moore R A et al. (1987) Opiate metabolism and excretion. Bailliers Clinical Anaethesiology. 1: 829–58.
  78. Novick D M, et al. (1981) Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther. 30: 353–62.
  79. GMC. (1993) Professional conduct and discipline: Fitness to practice. 2: 17.
  80. Medicines, ethics and practice: a guide for pharmacists. (1995) Pharmaceutical Press.
  81. Raistrick D, Bradshaw J, Tober G, et al. (1994) Leeds Dependence Questionnaire. Addiction. 89: 563–72.
  82. Ghodse H. (1995) Drugs and Addictive Behaviour. A Guide To Treatment. 2nd Edition, Blackwell Science Ltd. Oxford.
  83. Edwards G, Arif A and Hodgeson R. (1981) Nomenculture and classification of drug and alcohol-related problems: A WHO memorandum. Bulletin of the World Health Organisation. 59(2): 225–42.
  84. Psychoactive Substance Abuse. Diagnostic and Statistical Manual of the American Psychiatric Association, 4th Edition. (1994).
  85. Prochaska J O, DiClemente C and Norcross J. (1992) In search of how people change: applications to addictive behaviours. American Psychologist. 47: 1102–14.
  86. Bradley B, Philips G, Green L and Gossop M. (1989) Circumstances surrounding the initial lapse to opiate use following detoxification. British Journal of Psychiatry 1989, 154: 354–9.
  87. Cushman P and Dole V P. Detoxification of rehabilitated methadone maintained patients. Journal of the American Medical Association, 226: 747,752.
  88. Stimmel B, Goldberg J, Rotkopf E and Cohen M. Ability to remain abstinent after methadone detoxification: a six year study. Journal of the American Medical Association, 237: 1216–20.
  89. Senay E C, Dorus W, Goldberg F and Thornton W. Withdrawal from methadone maintenance: rate of withdrawal and expectation. Archives of General Psychiatry, 34: 361–7.
  90. Hall S M. (1979) The abstinence phobia. In: NA Krasnegor (ed). Behavioural Analysis of Substance Abuse, NADI Research Monograph 25. US National Institute on Drug Abuse.
  91. Ward J, Mattick R and Hall, W. (1992) Key Issues in Methadone Maintenance Treatment. New South Wales University Press, Australia.
  92. Fleming P, Davies A, Dickson A, et al (1994) Working with pregnant women who misuse drugs. Wessex Drugs Forum.
  93. Dubble, Dunne, Aldridge T and Kearney P. Registering Concern, Community Care, 12/3/87.
  94. Reiger D A, Farmer M E, Rae D S, et al. (1990) Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study. Journal of the American Medical Association, 264: 2511–8.
  95. Strang J. (1988) Editorial: Changing injecting practices: Blunting the habit. British Journal of Addiction 83: (3).
  96. Weber R, Ledergerber B, Poravil M, et al. (1990) Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone, British Medical Journal, 301: 1362–5.